These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36651087)

  • 1. Biologics in pediatric psoriasis.
    Wang WM; Jin HZ
    J Dermatol; 2023 Apr; 50(4):415-421. PubMed ID: 36651087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of pediatric plaque psoriasis using biologics.
    Lansang P; Bergman JN; Fiorillo L; Joseph M; Lara-Corrales I; Marcoux D; McCuaig C; Pope E; Prajapati VH; Li SZJ; Landells I
    J Am Acad Dermatol; 2020 Jan; 82(1):213-221. PubMed ID: 31150699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability and long-term outcomes of biologic therapies in psoriasis.
    Rusiñol L; Carmona-Rocha E; Puig L
    Expert Rev Clin Immunol; 2024; 20(1):71-82. PubMed ID: 37610817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of the efficacy and safety of plaque psoriasis treatment by TNF-α and IL-17A inhibitor biologics in patients who received the inactivated SARS-CoV-2 vaccine.
    Ye S; Sun H; Xu Z; Xu B; Wu N; Wu J
    Immun Inflamm Dis; 2023 Jul; 11(7):e938. PubMed ID: 37506146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the efficacy of biologics and clinical plaque psoriasis subtypes in Japanese patients: A single-center pilot study.
    Ito K; Bayaraa B; Imafuku S
    J Dermatol; 2019 Dec; 46(12):1160-1165. PubMed ID: 31556161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics and Psoriasis: The Beat Goes On.
    Kim HJ; Lebwohl MG
    Dermatol Clin; 2019 Jan; 37(1):29-36. PubMed ID: 30466686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.
    Prignano F; Pescitelli L; Trovato E; DI Cesare A; Cuccia A; Mazzatenta C; Pellegrino M; Marsili F; Castelli A; Brandini L; Niccoli MC; Taviti F; Ricceri F; Panduri S; Buggiani G; Ghilardi A; Rubegni P; Romanelli M; Pimpinelli N
    Ital J Dermatol Venerol; 2022 Dec; 157(6):469-479. PubMed ID: 35785927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab for treating plaque psoriasis.
    Rothstein B; Gottlieb A
    Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics in pediatric psoriasis - efficacy and safety.
    Dogra S; Mahajan R
    Expert Opin Drug Saf; 2018 Jan; 17(1):9-16. PubMed ID: 29022425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of antiphospholipid autoantibodies associated with biologics treatment for psoriasis.
    Li L; Toyama S; Mizuno Y; Yamamoto T; Hiroshima A; Koyama A; Taira H; Sugimoto E; Ito Y; Awaji K; Tateishi S; Kanda H; Asano Y; Sato S; Shibata S
    Sci Rep; 2024 Jul; 14(1):15975. PubMed ID: 38987260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
    Pinter A; Puig L; Schäkel K; Reich A; Zaheri S; Costanzo A; Tsai TF; Smith SD; Lynde C; Brnabic A; Reed C; Hill J; Schuster C; Riedl E; Paul C
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2087-2100. PubMed ID: 35766124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
    Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
    Ten Bergen LL; Petrovic A; Krogh Aarebrot A; Appel S
    Scand J Immunol; 2020 Oct; 92(4):e12946. PubMed ID: 32697374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
    Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
    J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
    Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L
    Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis.
    Green LJ; Yamauchi PS; Kircik LH
    J Drugs Dermatol; 2019 Aug; 18(8):776-788. PubMed ID: 31424708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis.
    Gisondi P; Geat D; Conti A; Dapavo P; Piaserico S; De Simone C; Bianchi L; Costanzo A; Malagoli P; Malara G; Micali G; Naldi L; Offidani A; Patrizi A; Prignano F; Parodi A; Rongioletti F; Calzavara-Pinton P; Girolomoni G
    Expert Rev Clin Immunol; 2020 Jun; 16(6):591-598. PubMed ID: 32419534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
    Al-Janabi A; Alabas OA; Yiu ZZN; Foulkes AC; Eyre S; Khan AR; Reynolds NJ; Smith CH; Griffiths CEM; Warren RB;
    JAMA Dermatol; 2024 Jan; 160(1):71-79. PubMed ID: 38055239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologics in the treatment of pustular psoriasis.
    Wang WM; Jin HZ
    Expert Opin Drug Saf; 2020 Aug; 19(8):969-980. PubMed ID: 32615817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.